Dr. Tiacci on Vemurafenib and Rituximab Combo in Hairy Cell Leukemia
Enrico Tiacci, MD, discusses updated data of a phase II trial investigating the combination of vemurafenib and rituximab for patients with relapsed/refractory hairy cell leukemia.
Dr. Tiacci on Standard of Care in Hairy Cell Leukemia Treatment
Enrico Tiacci, MD, discusses the current treatment options for patients with hairy cell leukemia. Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine.
Dr. Tiacci on Vemurafenib/Rituximab Combo in HCL
Enrico Tiacci, MD, discusses safety and efficacy results of a trial evaluating the BRAF inhibitor vemurafenib combined with rituximab in hairy cell leukemia.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512